Advertisement

Person › Details
Sofie Van Gijsel (Galapagos N.V. (Euronext + Nasdaq: GLPG))
Van Gijsel, Sofie (Galapagos 201812 Director IR)
![]() |
Organisation | Galapagos N.V. (Euronext + Nasdaq: GLPG) |
Group | Galapagos (Group) | |
![]() |
Product | public relations / investor relations / marcom (services) |
Product 2 | drug discovery services | |
Galapagos N.V.. (12/21/18). "Press Release: Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference". Mechelen.
Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8 & 9, 2019.
Onno van de Stolpe, CEO, will present on Wednesday, January 9 at 20:30 CET (11:30 a.m. Pacific time). The presentation will be live audio webcast and can be accessed via the following link: https://jpmorgan.metameetings.net/events/healthcare19/sessions/23994-galapagos-nv/webcast. A replay of the webcast will be available for 90 days on the Galapagos' website at www.glpg.com.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at glpg www.glpg.com.
Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784
Sofie Van Gijsel
Director IR
+32 485 19 14 15
ir@glpg.com
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.
Record changed: 2020-03-28 |
Advertisement

More documents for Sofie Van Gijsel
- [1] Galapagos N.V.. (8/28/19). "Press Release: Transparency Notification – Gilead Holds 22% of Galapagos Shares". Mechelen....
- [2] Galapagos N.V.. (1/8/19). "Press Release: Sands Capital Reports 5.7% Holding in Galapagos". Mechelen....
- [3] Galapagos N.V.. (1/6/19). "Press Release: Galapagos Initiates NOVESA Phase 2a Trial in Patients with Systemic Sclerosis". Mechelen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top